
Vigil Neuroscience (VIGL) Stock Forecast & Price Target
Vigil Neuroscience (VIGL) Analyst Ratings
Bulls say
Vigil Neuroscience Inc is currently pursuing the development of therapeutics for neurodegenerative diseases, with its candidate VG-3927 demonstrating a favorable safety profile and target engagement, potentially supporting its once-daily dosing regimen. The company's commitment to utilizing biomarker data, specifically the nearly 50% dose-dependent reduction in TREM2 levels, indicates a strong engagement with target activity, which could substantiate the efficacy of their treatments. The ongoing study's comprehensive approach—incorporating blood/CSF biomarkers, imaging, and clinical outcomes—positions Vigil favorably for regulatory filing, which may enhance its market potential and support future growth in share value.
Bears say
Vigil Neuroscience has experienced significant pressure on its stock valuation, with shares declining by 26% following the recent ALEC TREM2 data readout, indicating growing investor concern. The company reported a net loss of $23.8 million in 4Q24 and a GAAP EPS of $(0.57), which fell short of analyst expectations, highlighting potential challenges in achieving commercial success. Additionally, the adjustment of the valuation discount rate to 35% resulted in a considerable reduction of the company’s target price from $24 to $13, raising further doubts about the stock's future performance amidst competitive pressures.
This aggregate rating is based on analysts' research of Vigil Neuroscience and is not a guaranteed prediction by Public.com or investment advice.
Vigil Neuroscience (VIGL) Analyst Forecast & Price Prediction
Start investing in Vigil Neuroscience (VIGL)
Order type
Buy in
Order amount
Est. shares
0 shares